Por favor, use este identificador para citar o enlazar este ítem:
https://doi.org/10.14670/HH-18-607
![](/digitum/image/email_logo.png)
![](/digitum/image/logo-facebook.png)
Registro completo de metadatos
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Abe, Yushi | - |
dc.contributor.author | Sato, Yu | - |
dc.contributor.author | Tanaka, Mamoru | - |
dc.contributor.author | Ochiai, Daigo | - |
dc.date.accessioned | 2023-09-11T08:32:41Z | - |
dc.date.available | 2023-09-11T08:32:41Z | - |
dc.date.issued | 2023 | - |
dc.identifier.citation | Histology and Histopathology Vol. 38, nº9 (2023) | es |
dc.identifier.issn | 0213-3911 | - |
dc.identifier.issn | 1699-5848 | - |
dc.identifier.uri | http://hdl.handle.net/10201/133787 | - |
dc.description.abstract | This paper describes the current status of studies and clinical trials on the use of mesenchymal stem cells (MSCs) and amniotic fluid stem cells (AFSCs) for complications of preterm birth (PTB), an urgent issue in the perinatal field. PTB is a serious challenge in clinical medicine that is increasing globally, and effective control of its complications is necessary for newborns’ subsequent long life. Classical treatments are inadequate, and many patients have PTB complications. A growing body of evidence provided by translational medicine and others indicates that MSCs, and among them, the readily available AFSCs, may be useful in treating PTB complications. AFSCs are the only MSCs available prenatally and are known to be highly antiinflammatory and tissue-protective and do not form tumors when transplanted. Furthermore, because they are derived from the amniotic fluid, a medical waste product, no ethical issues are involved. AFSCs are an ideal cell resource for MSC therapy in neonates. This paper targets the brain, lungs, and intestines, which are the vital organs most likely to be damaged by PTB complications. The evidence to date and future prospects with MSCs and AFSCs for these organs are described. | es |
dc.format | application/pdf | es |
dc.format.extent | 10 | es |
dc.language | eng | es |
dc.publisher | Universidad de Murcia, Departamento de Biologia Celular e Histiologia | es |
dc.relation | Sin financiación externa a la Universidad | es |
dc.rights | info:eu-repo/semantics/openAccess | es |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Amniotic fluid stem cell | es |
dc.subject | Preterm birth | es |
dc.subject.other | CDU::6 - Ciencias aplicadas::61 - Medicina::616 - Patología. Medicina clínica. Oncología::616.1 - Patología del sistema circulatorio, de los vasos sanguíneos. Transtornos cardiovasculares | es |
dc.title | Development of a new treatment for preterm birth complications using amniotic fluid stem cell therapy | es |
dc.type | info:eu-repo/semantics/article | es |
dc.identifier.doi | https://doi.org/10.14670/HH-18-607 | - |
Aparece en las colecciones: | Vol.38, nº9 (2023) |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
ee659af7-25b1-49c8-9b9b-9eadd15be39f.pdf | 760,78 kB | Adobe PDF | ![]() Visualizar/Abrir |
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons